Kyrre Emblem

Dr. Kyrre Emblem

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
GRGeir Ringstad
Geir Ringstad
LVLars M. Valnes
Lars M. Valnes
ADAnders M. Dale
Anders M. Dale
APAre H. Pripp
Are H. Pripp
SVSvein-Are S. Vatnehol
Svein-Are S. Vatnehol
PEPer Kristian Eide
Per Kristian Eide
To what extent does the subarachnoid cerebrospinal fluid (CSF) compartment communicate directly with the extravascular compartment of human brain tissue? Interconnection between the subarachnoid CSF compartment and brain perivascular spaces is reported in some animal studies, but with controversy, and in vivo CSF tracer studies in humans are lacking. In the present work, we examined the distribution of a CSF tracer in the human brain by MRI over a prolonged time span. For this, we included a reference cohort, representing close to healthy individuals, and a cohort of patients with dementia and anticipated compromise of CSF circulation (idiopathic normal pressure hydrocephalus). The MRI contrast agent gadobutrol, which is confined to the extravascular brain compartment by the intact blood-brain barrier, was used as a CSF tracer. Standardized T1-weighted MRI scans were performed before and after intrathecal gadobutrol at defined time points, including at 24 hours, 48 hours, and 4 weeks. All MRI scans were aligned and brain regions were segmented using FreeSurfer, and changes in normalized T1 signals over time were quantified as percentage change from baseline. The study provides in vivo evidence of access to all human brain subregions of a substance administered intrathecally. Clearance of the tracer substance was delayed in the dementia cohort. These observations translate previous findings in animal studies into humans and open new prospects concerning intrathecal treatment regimens, extravascular contrast-enhanced MRI, and assessment of brain clearance function.

4 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TBTracy T. Batchelor
Tracy T. Batchelor
EGElizabeth R. Gerstner
Elizabeth R. Gerstner
KEKyrre Emblem
Kyrre Emblem
DDDan G. Duda
Dan G. Duda
JKJayashree Kalpathy-Cramer
Jayashree Kalpathy-Cramer
RJRakesh K. Jain
Rakesh K. Jain
Significance: This study demonstrates that antiangiogenic therapy increases tumor blood perfusion in a subset of newly diagnosed glioblastoma patients, and that it is these patients who survive longer when this expensive and potentially toxic therapy is combined with standard radiation and chemotherapy. This study provides fresh insights into the selection of glioblastoma patients most likely to benefit from antiangiogenic treatments.

8 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PEPer Kristian Eide
Per Kristian Eide
SVSvein Are Sirirud Vatnehol
Svein Are Sirirud Vatnehol
KEKyrre Emblem
Kyrre Emblem
GRGeir Ringstad
Geir Ringstad
Pre-clinical research in rodents provides evidence that the central nervous system (CNS) has functional lymphatic vessels. In-vivo observations in humans, however, are not demonstrated. We here show data on CNS lymphatic drainage to cervical lymph nodes in-vivo by magnetic resonance imaging (MRI) enhanced with an intrathecal contrast agent as a cerebrospinal fluid (CSF) tracer. Standardized MRI of the intracranial compartment and the neck were acquired before and up to 24–48 hours following intrathecal contrast agent administration in 19 individuals. Contrast enhancement was radiologically confirmed by signal changes in CSF nearby inferior frontal gyrus, brain parenchyma of inferior frontal gyrus, parahippocampal gyrus, thalamus and pons, and parenchyma of cervical lymph node, and with sagittal sinus and neck muscle serving as reference tissue for cranial and neck MRI acquisitions, respectively. Time series of changes in signal intensity shows that contrast enhancement within CSF precedes glymphatic enhancement and peaks at 4–6 hours following intrathecal injection. Cervical lymph node enhancement coincides in time with peak glymphatic enhancement, with peak after 24 hours. Our findings provide in-vivo evidence of CSF tracer drainage to cervical lymph nodes in humans. The time course of lymph node enhancement coincided with brain glymphatic enhancement rather than with CSF enhancement.

15 January 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ASA. Gregory Sorensen
A. Gregory Sorensen
KEKyrre Emblem
Kyrre Emblem
PPPavlina Polaskova
Pavlina Polaskova
DJDominique Jennings
Dominique Jennings
HKHeisoog Kim
Heisoog Kim
RJRakesh K. Jain
Rakesh K. Jain
The abnormal vasculature of the tumor microenvironment supports progression and resistance to treatment. Judicious application of antiangiogenic therapy may normalize the structure and function of the tumor vasculature, promoting improved blood perfusion. However, direct clinical evidence is lacking for improvements in blood perfusion after antiangiogenic therapy. In this study, we used MRI to assess tumor blood perfusion in 30 recurrent glioblastoma patients who were undergoing treatment with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. Tumor blood perfusion increased durably for more than 1 month in 7 of 30 patients, in whom it was associated with longer survival. Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival. Cancer Res; 72(2); 402–7. ©2011 AACR.

18 August 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KEKyrre Emblem
Kyrre Emblem
KMKim Mouridsen
Kim Mouridsen
ABAtle Bjornerud
Atle Bjornerud
CFChristian T Farrar
Christian T Farrar
DJDominique Jennings
Dominique Jennings
ASA Gregory Sorensen
A Gregory Sorensen
Measurement of vessel caliber by magnetic resonance imaging (MRI) is a valuable technique for in vivo monitoring of hemodynamic status and vascular development, especially in the brain. Here, we introduce a new paradigm in MRI termed vessel architectural imaging (VAI) that exploits an overlooked temporal shift in the magnetic resonance signal, forming the basis for vessel caliber estimation, and show how this phenomenon can reveal new information on vessel type and function not assessed by any other noninvasive imaging technique. We also show how this biomarker can provide new biological insights into the treatment of patients with cancer. As an example, we demonstrate using VAI that anti-angiogenic therapy can improve microcirculation and oxygen saturation and reduce vessel calibers in patients with recurrent glioblastomas and, more crucially, that patients with these responses have prolonged survival. Thus, VAI has the potential to identify patients who would benefit from therapies.

7 January 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
Giorgio SeanoGiorgio Seano
Giorgio Seano
HNHadi T. Nia
Hadi T. Nia
KEKyrre Emblem
Kyrre Emblem
MDMeenal Datta
Meenal Datta
JRJun Ren
Jun Ren
RJRakesh K. Jain
Rakesh K. Jain